Back

Type 1 interferon supports B cell responses to polysaccharide antigens but is not required for MPL/TDCM adjuvant effects on innate B cells

Spurrier, A.; Jennings-Gee, J.; Haas, K.

2021-11-02 immunology
10.1101/2021.10.30.466603 bioRxiv
Show abstract

We previously described monophosphoryl lipid A (MPL) and synthetic cord factor, trehalose-6,6-dicorynomycolate (TDCM) significantly increases antibody (Ab) responses to T cell independent type 2 antigens (TI-2 Ags) in a manner dependent on B cell-intrinsic TLR4 expression as well as MyD88 and TRIF adapter proteins. Given the requirement for TRIF in optimal MPL/TDCM adjuvant effects and the capacity of MPL to drive type I IFN production, we aimed to investigate the extent to which adjuvant effects on TI-2 Ab responses depend on type I IFN receptor (IFNAR) signaling. We found IFNAR-/- mice had impaired early TI-2 Ag-induced B cell activation and expansion and that B cell-intrinsic type I IFN signaling on B cells was essential for normal antibody responses to TI-2 Ags, including haptenated Ficoll and the pneumococcal vaccine, Pneumovax23. However, MPL/TDCM significantly increased TI-2 IgM and IgG responses in IFNAR-/- mice. MPL/TDCM enhanced TI-2 Ab production primarily by activating innate B cells (B-1b and splenic CD23- B cells) as opposed to CD23+ enriched follicular B cells. In summary, our study highlights an important role for type I IFN in supporting early B cell responses to TI-2 Ags through B cell-expressed IFNAR, but nonetheless demonstrates an MPL/TDCM adjuvant significantly increases TI-2 Ab responses independently of type I IFN signaling and does so by predominantly supporting increased polysaccharide-specific Ab production by innate B cell populations. Key pointsO_LIB cell-intrinsic IFNAR expression promotes TI-2 Ab responses. C_LIO_LIMPL/TDCM adjuvant effects are independent of type 1 IFN. C_LIO_LIMPL/TDCM promotes TI-2 Ab responses by innate B cells. C_LI

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
The Journal of Immunology
146 papers in training set
Top 0.1%
20.3%
2
Frontiers in Immunology
586 papers in training set
Top 0.5%
10.5%
3
Immunology
29 papers in training set
Top 0.1%
8.8%
4
Vaccine
189 papers in training set
Top 0.6%
5.1%
5
ImmunoHorizons
21 papers in training set
Top 0.1%
5.1%
6
Scientific Reports
3102 papers in training set
Top 26%
4.5%
50% of probability mass above
7
PLOS ONE
4510 papers in training set
Top 33%
4.5%
8
mBio
750 papers in training set
Top 5%
2.7%
9
Molecular Immunology
14 papers in training set
Top 0.1%
2.6%
10
Clinical Immunology
21 papers in training set
Top 0.2%
2.2%
11
Journal of Immunological Methods
24 papers in training set
Top 0.1%
2.2%
12
Journal of Leukocyte Biology
40 papers in training set
Top 0.2%
1.7%
13
European Journal of Immunology
57 papers in training set
Top 0.3%
1.5%
14
PLOS Pathogens
721 papers in training set
Top 6%
1.4%
15
Glycobiology
30 papers in training set
Top 0.1%
1.3%
16
iScience
1063 papers in training set
Top 21%
1.3%
17
The Journal of Infectious Diseases
182 papers in training set
Top 3%
1.3%
18
Infection and Immunity
103 papers in training set
Top 0.5%
1.3%
19
Mucosal Immunology
42 papers in training set
Top 0.2%
1.0%
20
Immunology & Cell Biology
11 papers in training set
Top 0.1%
1.0%
21
Cytotherapy
14 papers in training set
Top 0.3%
0.9%
22
Frontiers in Physiology
93 papers in training set
Top 5%
0.9%
23
Vaccines
196 papers in training set
Top 2%
0.8%
24
npj Vaccines
62 papers in training set
Top 0.4%
0.8%
25
Transfusion
18 papers in training set
Top 0.2%
0.8%
26
Clinical and Experimental Immunology
12 papers in training set
Top 0.1%
0.8%
27
EMBO reports
136 papers in training set
Top 7%
0.7%
28
Cellular and Molecular Life Sciences
84 papers in training set
Top 0.9%
0.7%
29
Cancers
200 papers in training set
Top 5%
0.7%
30
Frontiers in Genetics
197 papers in training set
Top 12%
0.5%